From developing rapid-response vaccines to personalized cancer treatments, RNA is the future of medicine. However, multiple challenges remain in developing a successful therapeutic including the fine-tuning of cellular regulation, achieving efficient translation, and limiting innate immune responses. We have combined our unique portfolio of cutting-edge capabilities to create the eMERGE platform, the only comprehensive solution for RNA characterization and optimization. Discover how we can help you reduce development risks and reach the clinic with confidence.

The use of small oligonucleotides to regulate RNA levels and splicing has the potential to revolutionize the treatment of previously undruggable diseases. To be effective, oligonucleotides such as siRNAs and anti-miRs need to be designed to target accessible regions of genes. Furthermore, off-target binding frequently occurs which can reduce overall efficacy and produce side effects. We have combined our portfolio of proprietary technologies to characterize targets and provide comprehensive evaluations of off-target activity.

To be effective, a therapeutic has to target the right gene at the right location. To succeed in the clinic, off-targets need to be identified as soon as possible. With our unique portfolio of proprietary technologies, we provide solutions for holistic studies of target biology and therapeutic activity.

Eclipsebio was founded to develop unique technologies that provide robust, unparalleled insights into understanding RNA activity and function. To support our academic partners and their groundbreaking discoveries, we have created a portfolio of proprietary assays that reveal different aspects of RNA biology. Learn how our solutions support investigations into multiple aspects of RNA biology, from deep-profiling of a single RNA to transcriptome-wide mapping of miRNA activity.